Take note of This News: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

 

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) stock observed trading -53.12% off 52-week high price. On the other end, the stock has been noted 94.29% away from low price over the last 52-weeks. The stock disclosed a move of 11.64% away from 50 day moving average and -15.84% away from 200 day moving average. Moving closer, we can see that shares have been trading 0.54% off 20-day moving average.

KalVista Pharmaceuticals, Inc. (KALV) recently provided an operational update and released financial results for the fiscal year ended April 30, 2020.

Fourth Quarter and Full Year Financial Results:

Revenue: Revenue was $3.8M for the three months ended April 30, 2020, contrast to $2.9M for the same period in the previous fiscal year. Revenue was $12.7M for the fiscal year ended April 30, 2020, contrast to $16.1M for the previous fiscal year. All of the revenue recognized in the fiscal year ended April 30, 2020 was recognized from deferred revenue that existed at the starting of the period. No future revenue exists under the Merck Option Contract.

R&D Expenses: Research and development expenses were $9.5M for the three months ended April 30, 2020, contrast to $11.1M for the same period in the previous fiscal year. The decrease in spending during the quarter was primarily Because of the conclusion of the Phase 2 clinical trial for KVD001 in the previous quarter. Research and development expenses were $40.2M for the fiscal year ended April 30, 2020, contrast to $35.0M for the previous fiscal year. The increase in spending in the fiscal year ended April 30, 2020 primarily reflects increased costs related to the ongoing clinical trial for KVD900 as well as increased expenses on preclinical activities.

G&A Expenses: General and administrative expenses were $3.3M for the three months ended April 30, 2020, contrast to $3.0M for the same period in the previous fiscal year. General and administrative expenses were $13.0M for the fiscal year ended April 30, 2020, contrast to $10.9M for the previous fiscal year. The increase in G&A expenses was primarily Because of a raise in compensation related expenses and to a lesser extent, increases in commercial planning expenses, professional fees, and insurance costs.

Net Loss: Net loss was $6.6M, or $(0.37) per weighted average basic and diluted share, for the three months ended April 30, 2020, contrast to net loss of $8.5M, or $(0.49) per weighted average basic and diluted share for the same period in the previous fiscal year. Net loss was $29.1M, or $(1.64) per weighted average basic and diluted share for the fiscal year ended April 30, 2020, contrast to net loss of $20.8M, or $(1.38) per weighted average basic and diluted share in the previous fiscal year. The decrease in net loss and net loss per share in the three months ended April 30, 2020 as contrast to the same period in the previous fiscal year primarily resulted from reduced research and development spending Because of the completion of the Phase 2 clinical trial for KVD001 in the previous quarter. The increase in net loss and net loss per share in year ended April 30, 2020 was primarily related to the ramp up of research and development activities in the current year contrast to the previous fiscal year.

Cash Position: Cash, cash equivalents and marketable securities were $67.7M as of April 30, 2020, contrast to $100.8M as of April 30, 2019. The decrease in the net cash position was Because of increased spending, primarily on research and development activities during the year ended April 30, 2020 contrast to the previous fiscal year.

USA based company KalVista Pharmaceuticals, Inc. moved with change of -3.20% to $10.89 with the total traded volume of 83833 shares in recent session versus to an average volume of 145.49K. KALV’s shares are at -24.01% for the quarter and driving a -48.75% return over the course of the past year and is now at -38.85% since this point in 2018.  Right now, the stock beta is 2.47. The average volatility for the week and month was at 7.45% and 9.53% respectively. There are 17.84M shares outstanding and 16.09M shares are floated in market.

Leave a Reply

Your email address will not be published. Required fields are marked *